An Update on Scientific Advances and Clinical Strategies in Chronic Obstructive Pulmonary Disease (COPD) from the ATS 2017 International Conference

The 2017 American Thoracic Society (ATS) International Conference was held in Washington, DC, May 19–24, 2017. As a leading meeting in respiratory medicine, dedicated to advancing the clinical and scientific understanding of pulmonary diseases, critical illnesses, and sleep-related breathing disorders, the ATS Conference attracts thousands of participants from around the world. The 2017 ATS conference featured 6700 original research projects, 500 sessions, and 800 speakers. In this activity, 2 experts summarize the key learnings on COPD from this year’s conference.

Target Audience

This activity has been designed to meet the educational needs of health care professionals responsible for the diagnosis, treatment, or management of patients with COPD.

Educational Objectives 

Upon completion of this activity, participants will be better able to do the following:

  1. Identify recent advances in the understanding of COPD pathophysiology, genetics, disease progression, and comorbidities
  2. Discuss recent advances in COPD treatment

Faculty

 

Nicola A. Hanania, MD, MS
Associate Professor of Medicine
Director
Airways Clinical Research Center
Baylor College of Medicine
Houston, Texas

Fernando J. Martinez, MD, MS
Chief
Division of Pulmonary and Critical Care Medicine
Weill Cornell Medical College
New York, New York

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Relationship Identified With:

Nicola A. Hanania, MD, MS

Consultant/Advisor: AstraZeneca, GlaxoSmithKline plc, Mylan N.V., Novartis AG, Sanofi

Grant/Research Support: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Mylan N.V.

Fernando J. Martinez, MD, MS

Consultant/Advisor: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG, Pearl Therapeutics, Inc., Theravance Biopharma

Research Grant: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc

Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG

Royalties/Patents: UpToDate, Inc.

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by independent educational grants from GlaxoSmithKline LLC and AstraZeneca.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. 

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.


Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., GlaxoSmithKline LLC and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
06/19/2017
Course expires: 
06/18/2018
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician

Accreditation Period

Course opens: 
06/19/2017
Course expires: 
06/18/2018
Please login or register to take this course.